Alkermes Reports Minimal Consumer Weight Gain In Long-Term Clinical Trial Of Lybalvi Antipsychotic

Alkermes plc announced that participants its four-year clinical trial of Lybalvi (olanzapine and samidorphan) for adults with schizophrenia, schizophreniform disorder, or bipolar I disorder had minimal weight gain. The participants who completed the four-year treatment period had an average weight gain of 1.47 kg, and their average waist circumference increased by 0.61 cm.

Lybalvi is a once-daily, oral atypical antipsychotic approved in the U.S. for the treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed . . .